Full name
The REALITI-C Study: Real world effectiveness of mepolizumab in treating chronic obstructive pulmonary disease (COPD)
NCT Number
GSK Study ID 223598
Geography
US
Non-US
Locations
TBD
Primary Endpoints
- Annualized rate of moderate/severe exacerbations
- Timeframe: 12 months pre-exposure period and 12 months following mepolizumab initiation
External Link
https://www.gsk-studyregister.com/en/trial-details/?id=223598
Order
3
Disease
Version
Phase
Observational
Status
Recruiting